GS
GMAB icon

GTS Securities’s Genmab GMAB Stock Holding History

GTS Securities’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-114,743
Closed -$2.37M – 1526
2025
Q2 		$2.37M Buy
+114,743
New +$2.36M 0.11% 150
2025
Q1 		– Sell
-74,356
Closed -$1.55M – 1362
2024
Q4 		$1.55M Buy
+74,356
New +$1.63M 0.08% 197
2024
Q1 		– Sell
-9,337
Closed -$297K – 4082
2023
Q4 		$297K Buy
+9,337
New +$293K ﹤0.01% 3211

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

GTS Securities's GMAB Position: Q3 2025 in Review

GTS Securities sold out of Genmab (GMAB) in Q3 2025, closing a stake of 114,743 shares — an estimated $2.37M sold.

GTS Securities first reported a position in GMAB in Q4 2023 and held it in 3 quarters. The position peaked at $2.37M in Q2 2025. 252 funds tracked by Wall St. Rank hold GMAB as of Q3 2025.

  • GTS Securities reported no remaining Genmab position as of Q3 2025 after selling out during the quarter.
  • GTS Securities sold 114,743 Genmab shares in Q3 2025, an estimated $2.37M.
  • GTS Securities first reported a position in Genmab in Q4 2023 and held it in 3 quarters.
  • GTS Securities's Genmab position peaked at $2.37M in Q2 2025.
  • 252 funds tracked by Wall St. Rank held Genmab as of Q3 2025.

Based on GTS Securities's 13F filing for Q3 2025, filed 14 Nov 2025.